lucentis 10 mg/ml soluţie injectabilă
novartis pharma ag - ranibizumabum - soluţie injectabilă - 10 mg/ml
ranivisio 10 mg/ml
polpharma biologics s.a. - polonia - ranibizumabum - sol inj. - 10mg/ml - medicamente pentru tulburari vasculare oculare medicamente pentru tratamentul neovascularizarii
ximluci 10 mg/ml
stada arzneimittel ag - germania - ranibizumabum - sol. inj. - 10mg/ml - medicamente pentru tulburari vasculare oculare medicamente pentru tratamentul neovascularizarii
lucentis solutie injectabila 10 mg/ml
novartis pharma ag - solutie injectabila - 10 mg/ml
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologice - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologice - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologice - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
lucentis
novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmologice - lucentis este indicat la adulți pentru:tratamentul de forma neovasculară (umedă) degenerescenta maculara legata de varsta (amd)tratamentul de insuficiență vizuale din cauza neovascularizație coroidiană (cnv)tratamentul de insuficiență vizuale din cauza edemului macular diabetic (emd)tratamentul tulburărilor vizuale datorită edemului macular secundar ocluzia venei retiniene (filiala rvo sau centrale rvo).
synagis 50 mg pulbere şi solvent pentru soluţie injectabilă
abbvie ltd - palivizumabum - pulbere şi solvent pentru soluţie injectabilă - 50 mg
synagis 100 mg/ml soluţie injectabilă
abbvie deutschland gmbh & co.kg - palivizumabum - soluţie injectabilă - 100 mg/ml